Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if bevacizumab, when given in
combination with gemcitabine, docetaxel, melphalan and carboplatin, or with topotecan,
cyclophosphamide and melphalan (if you are older than 60 or have an allergy to carboplatin),
can help to control ovarian cancer during a stem cell transplant. The safety of this drug
combination will also be studied.